All Categories
New Data Highlight Artera’s MMAI Consistency Across Diverse Patient...
Five abstracts spanning global patient cohorts and U.S. cooperative trials reinforce the prognostic and predictive power of A [...]
Investment Reports Andre Esteva Interview
Artera is a precision medicine company developing artificial intelligence tools to support personalized cancer treatment deci [...]
Rethinking ADT: AI Biomarkers in Intermediate-Risk Prostate Cancer
A recently published cost-effectiveness analysis has found that using the ArteraAI Prostate Test to guide androgen deprivatio [...]
Is Your Pathology AI Really Ready?
AI is advancing rapidly in pathology, with new FDA clearances, reimbursement pathways, and growing adoption across health sys [...]
Real-World Validation of an Imaging-Only AI Model in Localized...
Xinglei Shen presents a real-world validation of ArteraAI's multimodal risk model and a next-generation imaging-only version. [...]
A Faster Path to Breast Cancer Prognosis
An FDA-cleared AI tool offers shorter turnaround times and supports precision oncology Chemotherapy decision-making in early- [...]
Personalizing Prostate Cancer Care with the ArteraAI Prostate Test...
Artificial intelligence is transforming nearly every aspect of healthcare, but what does that actually mean for men with pros [...]
AI Finds New Applications in Oncologic Surgery, Drug and...
AI is rapidly moving beyond the realm of future promise and into everyday oncology practice. From enhancing surgical precisio [...]